Comparative bioavailability of elemental iron powders for repair of iron deficiency anemia in rats. Studies of efficacy and toxicity of carbonyl iron

1978 ◽  
Vol 31 (4) ◽  
pp. 566-571 ◽  
Author(s):  
P V Sacks ◽  
D N Houchin
1987 ◽  
Vol 46 (6) ◽  
pp. 1029-1034 ◽  
Author(s):  
V R Gordeuk ◽  
G M Brittenham ◽  
M Hughes ◽  
L J Keating ◽  
J J Opplt

Blood ◽  
1986 ◽  
Vol 67 (3) ◽  
pp. 745-752 ◽  
Author(s):  
VR Gordeuk ◽  
GM Brittenham ◽  
CE McLaren ◽  
MA Hughes ◽  
LJ Keating

Abstract To determine if elemental carbonyl iron powder is safe and effective therapy for iron deficiency anemia, 20 nonanemic and 32 anemic volunteers were studied. Single doses of 1,000 to 10,000 mg of carbonyl iron (15 to 150 times the 65 mg of iron in the usual dose of ferrous sulfate) were tolerated by nonanemic volunteers with no evidence of toxicity and only minor gastrointestinal side effects. Anemic volunteers (menstruating women who had previously donated blood) were treated with several regimens providing 1,000 to 3,000 mg of carbonyl iron daily in one to three doses for 8 to 28 days. After 12 weeks anemia was corrected in 29 of 32 patients, and serum ferritin was greater than 12 micrograms/L in 14. Hemoglobin regeneration proceeded at a rate similar to that described for therapy with oral iron salts and parenteral iron dextran. There was no evidence of hematologic, hepatic, or renal toxicity, but mild gastrointestinal side effects occurred in a majority of anemic volunteers. Carbonyl iron is an effective, inexpensive treatment for iron deficiency anemia, is accompanied by tolerable side effects and may have an advantage over therapy with iron salts by substantially reducing or eliminating the risk of iron poisoning in children.


PEDIATRICS ◽  
1992 ◽  
Vol 89 (2) ◽  
pp. 358-358
Author(s):  
CHARLES R. FIKAR

To the Editor.— There is an error in the new edition of The Harriet Lane Handbook concerning the concentration of iron in Fer-in-sol syrup.1 The text states that the number of milligrams of elemental iron is 18 milligrams per milliliter. According to the package insert, the concentration is actually 18 milligrams per 5 milliliters. Children being treated with this iron preparation potentially would be greatly underdosed if the printed information in the handbook is used by a physician in determining a treatment plan for iron deficiency anemia.


Nutrients ◽  
2021 ◽  
Vol 13 (3) ◽  
pp. 968
Author(s):  
Katia Urso ◽  
Javier Leal Martínez-Bujanda ◽  
Jaime Moscoso del Prado

Oral iron supplementation constitutes the first line treatment for iron deficiency anemia (IDA), with daily doses between 80 mg and 200 mg of elemental iron. Ferrous salts, such as ferrous sulphate (FeSO4), while efficacious, frequently give rise to gastrointestinal side effects. In the present paper we attempted to directly compare the efficacy of an alternative to the FeSO4 formulation, which presents a better tolerability profile, iron protein succinylate (Ferplex®). In a diet-induced anemia model, rats were treated by oral gavage with vehicle, FeSO4, or Ferplex® at a human-dose equivalent of 80 mg and 200 mg of elemental iron. We evaluated the change in anemia-related hematological and biochemical parameters, conducting a histological examination of the intestine at sacrifice. Results indicate that both types of iron supplementation are equally effective in the treatment of IDA, restoring hemoglobin, hematocrit, erythrocytes, free iron and transferrin levels in 15 days, with no statistical differences between treated groups and control. The impact of anemia on body weight was also attenuated following treatment with both iron supplements. Thrombocyte and reticulocyte levels, altered by the anemic condition, returned to homeostasis after 15 days of either FeSO4 or Ferplex® treatment. Importantly, the lower and higher doses of iron were equally effective, thus supporting the current school of thought which states that lower therapeutic doses are sufficient for management of IDA. In addition, the study shows for the first time that oral treatment with Ferplex® does not increase serum hepcidin. Finally, Ferplex® induced minimal iron depositions in the intestinal tissue compared to FeSO4.


2019 ◽  
Vol 6 (4) ◽  
pp. 1519
Author(s):  
Sanghamitra Ray ◽  
Jagdish Chandra ◽  
Sunita Sharma

Background: Iron deficiency anemia is a major cause of morbidity in developing countries like India. The aim of the study was to assess abnormalities of platelet count in iron deficiency anemia and to relate the severity of thrombocytosis with severity of anemia and its association with erythropoietin (EPO) level.Methods: A prospective observational study comprising of 200 children below 18 years confirmed to have IDA. Erythropoietin (EPO) level was done in patients who had thrombocytosis. Degree of thrombocytosis was correlated with EPO and also with ferritin, haematological indices like hemoglobin and MCV (mean corpuscular volume) and blood counts were followed up while on iron therapy for one month.Results: Thrombocytosis was noted in 24.5%. In 75.5% thrombocytosis was mild. Platelet had negative correlation with Hb (hemoglobin). EPO was elevated in 67.35% of thrombocytosis. EPO showed negative correlation with Hb and Ferritin and positive correlation with platelet however, these were non-significant. All patients were treated with standard preparation of ferrous fumarate (33mg elemental iron every 5 ml) in a dose of 3mg/kg/day of elemental iron along with appropriate dietary advice.  On one month follow up 92% of the study population showed normalization of platelet count.Conclusions: Nearly One-fourth of children had thrombocytosis. Platelet count was inversely related to Hb and ferritin level. EPO was increased in two-third cases of thrombocytosis and showed positive correlation with platelet count. As authors excluded patients with severe IDA requiring blood transfusion, authors did not get any thrombocytopenia in present study.


2019 ◽  
pp. 11-15

Efecto de la administración de sulfato ferroso dos veces por semana para la reducción de la anemia en niños de 6 a 35 meses de edad, durante 6 meses y durante 12 meses de suplementación en comunidades rurales de Ancash, Perú Effect of ferrous sulfate administration twice a week to reduce anemia in children 6 to 35 months of age, during once and twice six month supplementations in rural communities from the Ancash Region, Peru Andrés Morán Tello, Dante Rodríguez Rodríguez, Marlene Rojas Córdova, Régulo Canchaya Alvarez Cáritas del Perú, apartado postal 89, Lima 100 Fondo Minero Antamina, Huaraz, Ancash. DOI: https://doi.org/10.33017/RevECIPeru2012.0003/ RESUMEN La anemia por deficiencia de hierro es de elevada prevalencia en el Perú. Afecta principalmente a los niños menores de 3 años. En los últimos 10 años la prevalencia ha disminuido poco y permanece elevada sobre todo en la población que vive en la sierra y las áreas rurales. Cáritas del Perú desarrolló en la región Ancash entre el año 2007 y el 2011 el Proyecto Ally Micuy, con el apoyo del Fondo Minero Antamina, en el cual se logró reducción apreciable de la desnutrición crónica y la anemia infantil. Nuestro objetivo es mostrar la eficacia de la administración dos veces por semana de suplemento de sulfato ferroso para la reducción de la anemia en niños de 6 a 35 meses de edad, en comunidades rurales de Ancash, Perú. Esta es una investigación observacional retrospectiva. En el proyecto Ally Micuy se determinó el nivel de hemoglobina inicial de niños de 6 a 35 meses, mediante fotómetro HemoCue. Según los niveles de hemoglobina, se administró sulfato ferroso entre 1 a 2 mg de hierro elemental por kilo de peso corporal por vez, dos veces por semana, como dosis preventiva y de 3 a 5 mg de hierro elemental por kilo de peso corporal por vez, dos veces por semana, como dosis terapéutica. La suplementación de sulfato ferroso estuvo a cargo de las Educadoras Comunales en Nutrición. Se analizó la hemoglobina a los 6 y 12 meses. Se observo que el porcentaje de niños de 6 a 35 meses con anemia bajó de 62.58% a 45.71%, después de un semestre de suplementación (n=4001). Al final del segundo semestre consecutivo de suplementación, el porcentaje de anemia bajó de 68.28% a 31.57% (n=2623). La concentración promedio de hemoglobina fue 10.29gr/dl, 10.78gr/dl y 11.23gr/dl, al inicio, a los 6 y a los 12 meses de suplementación, respectivamente. Por lo tanto se concluye que la suplementación hecha por las Educadoras Comunales de Nutrición dos veces por semana es efectiva para la reducción de la anemia en niños de 6 a 35 meses de edad. La disminución de la prevalencia de la anemia en los niños mediante administración de sulfato ferroso es mucho mayor cuando los niños reciben suplementación supervisada durante dos semestres consecutivos. Descriptores: Anemia ferropénica, suplementación con sulfato ferroso. ABSTRACT Iron-deficiency anemia is highly prevalent in Peru. It mainly affects children under 3 years. In the past 10 years the prevalence has declined slightly and remains high especially in the population living in the mountains and rural areas. Caritas Peru in the Ancash region developed between 2007 and 2011 Micuy Ally Project, with support from the Antamina Mining Fund, which was achieved significant reduction in chronic malnutrition and anemia in children. Our objective is to show the efficacy of twice weekly administration of ferrous sulfate supplements for reducing anemia in children 6 to 35 months of age in rural communities in Ancash, Peru. This is a retrospective observational research. The project was determined Ally Micuy initial hemoglobin level of children 6 to 35 months, using HemoCue photometer. According to the levels of hemoglobin, ferrous sulfate was administered 1 to 2 mg of elemental iron per kilo of body weight per time, twice a week as a preventive dose and 3 to 5 mg of elemental iron per kilo of body weight once twice a week as a therapeutic dose. Ferrous sulfate supplementation was provided by the Community Educational Nutrition. Hemoglobin was analyzed at 6 and 12 months. We observed that the percentage of children aged 6 to 35 months with anemia decreased from 62.58% to 45.71% after one semester of supplementation (n = 4001). After the second consecutive semester of supplementation, the percentage of anemia decreased from 68.28% to 31.57% (n = 2623). The average concentration of hemoglobin was 10.29gr/dl, and 11.23gr/dl 10.78gr/dl at baseline, at 6 and 12 months of supplementation, respectively. Therefore, we conclude that supplementation made by the Nutrition Community Educational team twice a week is effective in reducing anemia in children 6 to 35 months of age. The decrease in the prevalence of anemia in children by administration of ferrous sulfate is much greater when the children are supervised supplementation during two consecutive semesters Keywords: Iron deficiency anemia, supplementation with ferrous sulfate.


2016 ◽  
Vol 24 (4) ◽  
pp. 746-753 ◽  
Author(s):  
Qiaosha Zhu ◽  
Yang Qian ◽  
Ying Yang ◽  
Weifeng Wu ◽  
Jingli Xie ◽  
...  

Blood ◽  
1986 ◽  
Vol 67 (3) ◽  
pp. 745-752
Author(s):  
VR Gordeuk ◽  
GM Brittenham ◽  
CE McLaren ◽  
MA Hughes ◽  
LJ Keating

To determine if elemental carbonyl iron powder is safe and effective therapy for iron deficiency anemia, 20 nonanemic and 32 anemic volunteers were studied. Single doses of 1,000 to 10,000 mg of carbonyl iron (15 to 150 times the 65 mg of iron in the usual dose of ferrous sulfate) were tolerated by nonanemic volunteers with no evidence of toxicity and only minor gastrointestinal side effects. Anemic volunteers (menstruating women who had previously donated blood) were treated with several regimens providing 1,000 to 3,000 mg of carbonyl iron daily in one to three doses for 8 to 28 days. After 12 weeks anemia was corrected in 29 of 32 patients, and serum ferritin was greater than 12 micrograms/L in 14. Hemoglobin regeneration proceeded at a rate similar to that described for therapy with oral iron salts and parenteral iron dextran. There was no evidence of hematologic, hepatic, or renal toxicity, but mild gastrointestinal side effects occurred in a majority of anemic volunteers. Carbonyl iron is an effective, inexpensive treatment for iron deficiency anemia, is accompanied by tolerable side effects and may have an advantage over therapy with iron salts by substantially reducing or eliminating the risk of iron poisoning in children.


Sign in / Sign up

Export Citation Format

Share Document